Attentional Bias in Body Dysmorphic Disorder (VAB)

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Sabine Wilhelm, Massachusetts General Hospital

ClinicalTrials.gov Identifier:

NCT01398904

First received: July 15, 2011

Last updated: August 31, 2012

Last verified: August 2012

History of Changes

Purpose

Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.

Condition
Body Dysmorphic Disorders

Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	Attentional Bias in Body Dysmorphic Disorder

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

Attention Pattern [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
Gaze tracking via an Eyelink II eye tracker will determine perception of visual information.

Secondary Outcome Measures:

Subjective Units of Distress Scale (SUDS) [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
Participants will provide a distress score based on the facial images observed.
Facial Attractiveness [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
Using a 9-point Likert scale, participants will rate the perceived most attractive and unattractive feature of their own and the control face.

Estimated Enrollment:	40
Study Start Date:	March 2011

Groups/Cohorts
Body dysmorphic disorder (BDD) Participants Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
Healthy Controls Males and females 18 years of age or older with ability to provide informed consent and understand study staff.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

The study will include 40 participants, consisting of 20 BDD participants and 20 matched healthy controls.

Criteria

Inclusion Criteria for BDD and healthy control participants:

males and females 18 years of age or older
sufficient fluency of English to understand study staff, procedures, and questionnaires
ability to provide informed consent

Inclusion for BDD participants only;

primary diagnosis of Diagnostic and Statistical Manual 4th Edition (DSM-IV-TR) BDD
BDD Yale-Brown Obsessive Compulsive Disorder score (Y-BOCS) of > 20
primary facial/head concern

Exclusion Criteria:

Major medical or neurological conditions
schizophrenia, schizoaffective disorder, or any other current lifetime DSM-IV psychotic disorder that is not attributable to delusional BDD
current suicidality
current homicidality

Exclusion criteria for healthy controls:

Any current Axis I psychiatric illness
history of BDD

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01398904

Locations

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Massachusetts General Hospital

Investigators

Principal Investigator:	Sabine Wilhelm, Ph. D.	Massachusetts General Hospital
Study Director:	Jennifer Greenberg, Psy. D.	Massachusetts General Hospital

More Information

Publications:

Deckersbach T, Savage CR, Phillips KA, Wilhelm S, Buhlmann U, Rauch SL, Baer L, Jenike MA. Characteristics of memory dysfunction in body dysmorphic disorder. J Int Neuropsychol Soc. 2000 Sep;6(6):673-81.

Phillips KA. Quality of life for patients with body dysmorphic disorder. J Nerv Ment Dis. 2000 Mar;188(3):170-5.

Phillips KA, Coles ME, Menard W, Yen S, Fay C, Weisberg RB. Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry. 2005 Jun;66(6):717-25.

Phillips KA, Menard W, Fay C, Pagano ME. Psychosocial functioning and quality of life in body dysmorphic disorder. Compr Psychiatry. 2005 Jul-Aug;46(4):254-60.

Savage CR, Baer L, Keuthen NJ, Brown HD, Rauch SL, Jenike MA. Organizational strategies mediate nonverbal memory impairment in obsessive-compulsive disorder. Biol Psychiatry. 1999 Apr 1;45(7):905-16.

Kelly MM, Walters C, Phillips KA. Social anxiety and its relationship to functional impairment in body dysmorphic disorder. Behav Ther. 2010 Jun;41(2):143-53. Epub 2009 Oct 7.

Maner JK, Holm-Denoma JM, Van Orden KA, Gailliot MT, Gordon KH, Joiner TE Jr. Evidence for attentional bias in women exhibiting bulimotypic symptoms. Int J Eat Disord. 2006 Jan;39(1):55-61.

Roefs A, Jansen A, Moresi S, Willems P, van Grootel S, van der Borgh A. Looking good. BMI, attractiveness bias and visual attention. Appetite. 2008 Nov;51(3):552-5. Epub 2008 Apr 15.

Carey P, Seedat S, Warwick J, van Heerden B, Stein DJ. SPECT imaging of body dysmorphic disorder. J Neuropsychiatry Clin Neurosci. 2004 Summer;16(3):357-9.

Janelle CM, Hausenblas HA, Fallon EA, Gardner RE. A visual search examination of attentional biases among individuals with high and low drive for thinness. Eat Weight Disord. 2003 Jun;8(2):138-44.

Responsible Party:	Sabine Wilhelm, Director, OCD & Related Disorders Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT01398904 History of Changes
Other Study ID Numbers:	2010P002912
Study First Received:	July 15, 2011
Last Updated:	August 31, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:

BDD

Additional relevant MeSH terms:

Body Dysmorphic Disorders
Somatoform Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 19, 2013

To Top